We were interested in developing oncolytic adenoviral vectors that can be administered systemically for the treatment of breast cancer. To restrict viral replication in breast tumor cells, we constructed mhTERTAd.sTbRFc, a 01/07-based adenoviral vector expressing the soluble form of transforming growth factor-b (TGFb) receptor II fused with the human Fc IgG1 (sTGFbRIIFc) gene, in which viral replication is under the control of a modified human telomerase reverse transcriptase (mhTERT) promoter. In addition, mhTERTAd.sTbRFc-mediated sTGFbRIIFc production targets the TGFb pathway known to contribute to the tumor progression of breast cancer metastasis. We chose to use the mhTERT promoter because it was found to be relatively more active (approximately 20 times) in breast cancer cells compared with normal human cells. We showed that infection of MDA-MB-231 and MCF-7 breast cancer cells for 48 h with mhTERTAd.sTbRFc produced high levels of sTGFbRIIFc (greater than 1 mg ml À1 ) in the medium. Breast cancer cells produced nearly a 6000-fold increase in viral titers during the 48 h infection period. However, mhTERTAd.sTbRFc replication was attenuated in normal cells. Infection of breast cancer cells with a replication-deficient virus Ad(E1 À ).sTbRFc also produced high levels of sTGFbRIIFc, but under these conditions, no detectable viral replication was observed. Adenoviral-mediated production of sTGFbRIIFc was shown to bind with TGFb-1, and to abolish the effects of TGFb-1 on downstream SMAD-3 phosphorylation. The administration of mhTERTAd.sTbRFc intravenously into MDA-MB-231 human xenograft-bearing mice resulted in a significant inhibition of tumor growth and production of sTGFbRIIFc in the blood. Conversely, intravenous injection of Ad(E1 À ).sTbRFc did not show a significant inhibition of tumor growth, but resulted in sTGFbRIIFc in the blood, suggesting that viral replication along with sTGFbRIIFc protein production is critical in inducing the inhibition of tumor growth. These results warrant future investigation of mhTERTAd.sTbRFc as an antitumor agent in vivo.
Introduction
Nearly 200 000 women are diagnosed with breast cancer, resulting in approximately 30 000 deaths each year in the United States. 1 Thus, there is a tremendous need to develop novel approaches to treat breast cancer. In recent years, tumor-specific replicating adenoviruses have been proposed as potential gene therapy vehicles to target cancer. [2] [3] [4] [5] Our long-term goals are to develop gene therapy approaches to treat breast cancer, and in this regard, we have chosen to develop oncolytic adenoviral (dl01/07 based) vectors. The adenoviral mutant 01/07 has two deletions in E1A (Rb and p300 binding) and replicates in cancer cells regardless of their genetic background. 6 In addition, we target the transforming growth factor-b (TGFb) pathway because high levels of TGFb protein and activated SMAD signaling are known to contribute to tumor progression and are associated with metastasis in breast cancer patients. [6] [7] [8] [9] [10] [11] [12] [13] Recently, we developed an oncolytic adenoviral vector (dl01/07 based) expressing the soluble form of TGFb receptor II fused with human Fc IgG1 (sTGFbRIIFc; Ad.sTbRFc).
14 To further restrict dl01/07 viral replication in breast tumor cells, we report here the construction of mhTERTAd.sTbRFc, a modified 01/07-based adenoviral vector expressing the sTGFbRIIFc gene, in which viral replication is under the control of a modified human telomerase reverse transcriptase (mhTERT) promoter. To examine the potential application of mhTERTAd.sTbRFc as an antitumor agent, we conducted in vitro and in vivo experiments using mhTERTAd.sTbRFc in human breast cancer models. Our data presented here show that it is feasible to create mhTERTAd.sTbRFc, achieve mhTERTAd.sTbRFc replication in breast cancer cells and simultaneously produce sTGFbRIIFc that can inhibit TGFb signaling in human breast cancer cells, and that intravenous administration of mhTERTAd.sTbRFc can inhibit tumor growth. These results warrant future investigation of mhTERTAd.sTbRFc as an antitumor agent in vivo.
Materials and methods
Cell culture HEK-293, MCF-7 and IMR-90 cells were obtained from ATCC, and MDA-MB-231 cells were obtained as described earlier. 12 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Mediatech Inc., Manassas, VA) containing 10% fetal bovine serum (FBS; Mediatech Inc.) and 1% penicillin-streptomycin (Invitrogen, Grand Island, NY).
Construction of recombinant viral vectors
To create mhTERTAd.sTbRFc, we cloned a 0.7 kb fragment of mhTERT 15 in a p01/07 shuttle plasmid to produce p01/07mhTERT shuttle vector in which the E1A 01/07 gene was controlled by the mhTERT promoter. The shuttle vector (PmeI digested) was recombined with PacI cut p01/07/sTbRFc in Escherichia coli BJ5183 to produce the pmhTERT01/07/sTbRFc viral backbone plasmid. The resulting plasmid was digested with PacI and transfected into HEK-293 cells to generate the mhTERTAd.sTbRFc adenovirus. Ad(E1 À ).sTbRFc, an E1min, replication-deficient adenovirus expressing sTGFbRIIFc, was created by homologous recombination procedures using established methods (Clontech, Palo Alto, CA). A replication-deficient adenorvirus devoid of any transgene Ad(E1 À ).Null has been described previously. 16 Adenoviruses were grown in HEK-293 cells and purified by double CsCl 2 density gradient.
Western blot analysis of sTGFbRIIFc produced by mhTERTAd.sTbRFc-or Ad(E1 À ).sTbRFc-infected cells Breast tumor cells (0.2 Â 10 6 cells per well in six-well plates) were plated in DMEM containing 10% FBS and incubated at 37 1C overnight. The next morning, cells were infected with 100 plaque-forming units (PFU) per cell of mhTERTAd.sTbRFc, Ad(E1 À ).sTbRFc or Ad(E1 À ).Null for 24 h. The cells were washed and incubated with DMEM without FBS for 24 h. Media and cells were subjected to western blot analysis as previously described. 16, 17 Blots were probed with antibody reactive against TGFbRII (H-567; Santa Cruz Biotechnology Inc., Santa Cruz, CA) or with actin protein (I-19; Santa Cruz Biotechnology).
ELISA assays of sTGFbRIIFc produced by mhTERTAd.sTbRFc-and Ad(E1 À ).sTbRFc-infected cells Supernatants obtained from mhTERTAd.sTbRFc-, Ad(E1 À ).sTbRFc-or Ad(E1 À ).Null-infected cells were analyzed for sTGFbRIIFc expression by enzyme-linked immunosorbent assay (ELISA) using the published method. 18 In brief, 96-well plates (Nunc, Roskilde, Denmark) were coated with an anti-human IgG-Fcspecific capture antibody (Santa Cruz Biotechnology), incubated with various dilutions of samples, followed by detection with a biotinylated anti-human TGFb RII antibody (R&D Systems, Minneapolis, MN). Detection was carried out with streptavidin-conjugated peroxidase using TMB/HRP substrate (BioFX Laboratories, Owing Mills, MD). After stopping the reaction with 1 N HCl, absorbance was measured at 450 nm using a SpectraMax Plus ELISA plate reader (Molecular Devices, Sunnyvale, CA). Standard curves of sTGFbRIIFc were used to calculate sTGFbRIIFc concentrations in the test samples.
Affinity purification of sTGFbRIIFc and binding of sTGFbRIIFc and TGFb1 MDA-MB-231 cells were infected with Ad.sTbRFc (100 PFU per cell) for 24 h. The medium was changed to serum-free medium for an additional 24 h. The medium was collected and applied to a Protein A Sepharose column. sTGFbRIIFc was eluted with 100 mM glycine buffer (pH 4). The eluted protein solution was neutralized by Tris buffer (pH 9.0), dialyzed against 20 mM Tris (pH 7.5) and stored at À70 1C.
For binding of TGFb-1 with sTGFbRIIFc, the TGFb-1 (Sigma, St Louis, MO) protein was mixed with sTGFbRIIFc, and incubated for 1 h at 4 1C. The complexes were mixed with Protein A Sepharose beads (Vector Laboratories, Burlingame, CA) and incubated at 4 1C for 1 h. Samples were centrifuged at 13 000 g at 4 1C for 1 min, and beads were washed four times with wash buffer (50 mM NaCl, 10 mM Tris-Cl, 5 mM EDTA, 1% Triton X-100, pH 7.4). Samples were resuspended in elution buffer (100 mM glycine buffer, pH 4) and centrifuged at 4 1C for 5 min. Proteins were neutralized with Tris-Cl (pH 9.0), subjected to western blot analysis and probed with anti-TGFb-1 (R&D Systems).
SMAD phosphorylation studies
Cells were plated in a six-well plate (4 Â 10 5 cells per well), and starved for 24 h in serum-free media. The cells were then washed with serum-free media before treatment with the indicated concentrations of recombinant TGFb-1 (Sigma) for 1 h. Cells were lysed in 250 ml lysis buffer containing 0.1 mM phenylmethylsulfonyl fluoride, sonicated and stored at À80 1C until further use. Equal amounts of cell lysates were separated by SDS-polyacrylamide gel electrophoresis on 10% acrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked in Blotto A for 1 h at room temperature and treated with phospho-SMAD-3 or SMAD-2/3 primary antibodies (Cell Signaling Technologies, Danvers, MA), followed by horseradish peroxidase (HRP)-conjugated bovine anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology). The blots were visualized by an enhanced chemiluminescence substrate (Amersham Biosciences, Piscataway, NJ).
Viral titer assay
Cells were plated in six-well plates at about 70% confluence and viral titers were examined using the published method 14, 19 with some modifications. Cells were infected with mhTERTAd.sTbRFc, Ad(E1 À ).sTbRFc or Ad(E1 À ).Null for 3 h at a multiplicity of infection of 100. Cells were washed with DMEM and incubated in 1 ml DMEM for an additional 1 h at 37 1C. At the end of the incubation, cells were washed and either collected in 0.5 ml growth media and frozen at À70 1C or were maintained in 2 ml of growth media for an additional 48 h. Media and cells were collected, and cells were subjected to three cycles of freezing and thawing to release the viruses. The total viruses from media and cells were serially diluted and added to monolayers of HEK-293 cells. After 3 h of incubation at 37 1C, infected HEK-293 cells were overlaid with 3 ml of 1.25% SeaPlaque agarose (Cambrex, East Rutherford, NJ) in growth media. Plaques were counted after 7-8 days of incubation using published methods. 20 To calculate the viral burst size, we divided viral titers at 48 h by the viral titers present in 3 h samples of various cell lines.
b-Gal assays
Cells were plated in a six-well plate (10 5 cells per well), and the next day were infected with adenoviral vectors expressing b-galactosidase (b-gal) for 24 h and examined for b-gal as described earlier. 16, 21 At the end of the incubation, cells were washed thrice with phosphatebuffered saline (pH 7.5) and lysed in 200 ml of 0.1 M Tris (pH 7.5) containing 0.1% Triton X-100. An aliquot (30 ml) was assayed for b-gal activity. Samples were treated with 100 ml 20 mM Tris (pH 7.5) containing 1 mM MgCl 2 , 450 mM b-mercaptoethanol and 150 mM O-nitrophenyl-b-D-galactopyranoside. Incubations were performed at 37 1C for 20 min, and the reaction was stopped by the addition of 100 ml per well of 1 M Na 2 CO 3 . Absorbance was determined at 420 nm. An A420 of 1.0 was defined as 1.0 unit of enzyme activity.
Evaluating antitumor responses in vivo in a breast tumor model MDA-MB-231 cells were injected subcutaneously in 4-week-old nude mice (Nu/Nu; 5 Â 10 6 cells per mouse). After about 1 week, when tumor sizes reached about 50 mm 3 (day 0), mhTERTAd.sTbRFc or Ad(E1 À ).sTbRFc or Ad(E1 À ).Null vectors were injected into the tail vein (2 Â 10 8 PFUs in 0.1 ml buffer per injection, a total of two injections on days 0 and 3). Tumor sizes were measured once a week using a digital caliper. Tumor volumes were calculated using the formula (a Â b 2 ) Â 0.523, in which a is the larger dimension and b the smaller dimension. At the end of the experiment, blood was collected by intracardiac puncture. All animal protocols were approved by IACUC of the NorthShore Research Institute.
Statistical analysis
For in vitro studies, experimental groups were compared by t-tests and two-tailed analysis, using GraphPad Prism software version 5 (GraphPad Software, San Diego, CA). For in vivo studies, comparisons among different treatment groups were carried out by the two-way analysis of variance (ANOVA) method and Bonferroni's post hoc test using the commercial software GraphPad Prism 5 (GraphPad Software). Po0.05 was considered to be a significant difference. All data points were presented as mean±s.e. (standard error).
Results
mhTERT promoter is much more active in breast tumor cells compared with normal cells Before creating mhTERT promoter-driven oncolytic viruses, we wanted to examine whether the mhTERT promoter has enhanced transcriptional activity in breast tumor cells compared with normal cells. Breast tumor (MDA-MB-231, MCF-7) and normal human cells (IMR-90) were exposed to either E1-deleted Ad(E1 À ).mhTERTLacZ, in which the mhTERT promoter drives the expression of a marker b-gal gene15, or E1-deleted Ad(E1 À ).CMVLacZ, in which the cytomegalovirus (CMV) promoter drives b-gal expression15. b-gal activity was quantified, and the results are shown in Figure 1 . All three cell lines produced high levels of b-gal activity when infected with Ad(E1 À ).CMVLacZ. b-Gal activity was relatively lower in each cell line infected with Ad(E1 À ).mhTERTLacZ. However, b-gal activity was markedly reduced in IMR-90 cells (Figure 1a) . To evaluate the relative activities of CMV and mhTERT promoters, we calculated the ratios of b-gal activities obtained from Ad(E1 À ).CMVLacZ vs Ad(E1 À ).mhTERTLacZ viruses in each cell line and are shown in Figure 1b . Although the CMV promoter was 6.1-and 7.7-fold more active than the mhTERT promoter in MDA-MB-231 and MCF-7 breast tumor cells, respectively, it was 115-fold more active than the mhTERT promoter in IMR-90 normal cells (Figure 1b) . These results indicate that the mhTERT promoter incorporated in the adenovirus backbone is about 20 times more active in breast cancer cells compared with normal human cells (P-values o0.05), favoring the use of the mhTERT promoter in oncolytic adenoviruses.
Construction of mhTERT-driven 01/07-based oncolytic adenovirus To examine the use of the mhTERT promoter in the context of 01/07 oncolytic viral replication, we constructed an oncolytic adenovirus, mhTERTAd.sTbRFc, using the homologous recombination method (Figure 2 ). In this viral construct, the mhTERT promoter regulates E1A expression. The key elements in this viral genome are mhTERT driving a mutant E1A region (01/07) and the expression cassette containing sTGFbRIIFc (part of E3 containing adenovirus death protein is left intact) (Figure 2 ). The rest Oncolytic adenovirus for breast cancer therapy Z Hu et al of the genomic structure of mhTERTAd.sTbRFc is identical to that of wild-type Ad5.
Infection of human breast cancer cells with mhTERTAd.sTbRFc and Ad(E1 À
).sTbRFc produces sTGFbRIIFc, which is secreted into the medium To investigate whether infection of breast cancer cells with mhTERTAd.sTbRFc and Ad(E1 À ).sTbRFc can produce the sTGFbRIIFc protein, we infected breast cancer cells with mhTERTAd.sTbRFc or Ad(E1 À ). sTbRFc and examined protein expression using western blot analysis. As shown in Figure 3a , infection of MDA-MB-231 and MCF-7 cells with mhTERTAd.sTbRFc showed a 60-80 kDa protein band of sTGFbRIIFc. Similarly, the extracellular media of mhTERTAd.sTbRFc also showed the presence of sTGFbRIIFc. Infection of cells with Ad(E1 À ).sTbRFc also produced sTGFbRIIFc, as shown by the presence of protein band in Ad(E1 À ). sTbRFc-infected cells. However, the sTGFbRIIFc protein was not detectable in cell lysates or in media of tumor cells infected with an Ad(E1 À ).Null (Figure 3a) . The amounts of sTGFbRIIFc in the supernatants of mhTERTAd.sTbRFc-and Ad(E1 À ).sTbRFc-infected breast cancer cells were quantified by the ELISA method. These amounts were found to be 2.22 and 1.13 mg ml À1 in MDA-MB-231 and MCF-7 cells, respectively, in mhTERTAd.sTbRFc-infected cells (Figure 3b ). Similar amounts of sTGFbRIIFc were found in Ad(E1 À ).sTbRFc-infected MDA-MB-231 and MCF-7 cells (Figure 3b) . These results indicate that infection of breast tumor cells with mhTERTAd.sTbRFc or Ad(E1 À ).sTbRFc can produce sTGFbRIIFc, which is subsequently released into media. Thus, incorporation of the mhTERT promoter driving E1A expression did not adversely affect the expression of sTGFbRIIFc.
mhTERTAd.sTbRFc-dependent production of sTGFbRIIFc in breast cancer cells can bind with TGFb-1 and inhibit TGFb-dependent SMAD-3 phosphorylation To examine the binding capacity of sTGFbRIIFc with TGFb, we incubated sTGFbRIIFc with TGFb-1 for 30 min at room temperature and mixed with Protein A Sepharose beads. The beads were centrifuged, and sTGFbRIIFc-TGFb complexes were eluted by denaturing buffer and subjected to western blot analysis. The blots were probed with anti-TGFb-1 antibody. The detection of TGFb-1 in the precipitate from sTGFbRIIFc-TGFb complexes indicated that secreted sTGFbRIIFc can form complexes with TGFb-1 (Figure 4a ).
To examine whether mhTERTAd.sTbRFc-mediated sTGFbRIIFc expression can lead to the inhibition of TGFb-dependent signal transduction, we examined the effect of sTGFbRIIFc on the inhibition of TGFbdependent SMAD-3 phosphorylation. MDA-MB-231 cells were exposed to TGFb-1 in the absence or presence of extracellular media containing the sTGFbRIIFc or purified sTGFbRIIFc protein. As shown in Figure 4b , TGFb-1 induced SMAD-3 phosphorylation in MDA-MB-231 cells, and this phosphorylation was inhibited by the crude media containing sTGFbRIIFc, as well as by purified sTGFbRIIFc (Figure 4b ). These results suggest that sTGFbRIIFc derived from mhTERTAd.sTbRFcinfected breast tumor cells is functionally active.
mhTERTAd.sTbRFc can replicate in human breast cancer cells, but has reduced replication potential in normal cells Next, we examined the replication potential of mhTERTAd.sTbRFc in breast cancer cells. Breast cancer cells were exposed to mhTERTAd.sTbRFc and viral titers were measured at 3 h (basal level) and at 48 h. As shown in . This titer was increased to 3.2 Â 10 6 in 48 h, indicating a 6189-fold increase in the viral titer. The increase in viral titers between 3 and 48 h is described here as the 'viral burst size' (Figures 5a and b) . A similar increase (6285-fold) in burst size was observed in MCF-7 cells (Figure 5b) . Conversely, infection of MDA-MB-231 or MCF-7 cells with Ad(E1 À ).sTbRFc or Ad(E1 À ).Null resulted in a less than twofold increase in viral burst size (data not shown), suggesting that Ad(E1 À ).sTbRFc is replication deficient in breast cancer cells. Using these viral replication assays, we also compared the burst size of mhTERTAd.sTbRFc in normal human cells. The burst size of mhTERTAd.sTbRFc was about 16-fold lower in IMR-90 cells compared with that in breast tumor cells (Figures 5a  and b) . The burst size of mhTERTAd.sTbRFc was about 16-fold higher in breast tumor cells compared with that in IMR-90 cells (Po0.001; Figure 5b ). These results indicate that mhTERTAd.sTbRFc replication is attenuated in normal cells while maintaining the replication potential in breast tumor cells.
Intravenous delivery of mhTERTAd.sTbRFc into MDA-MB-231 tumor-bearing mice causes inhibition of tumor growth and produces high levels of sTGFbRIIFc in blood Next, we conducted experiments to evaluate the in vivo efficacy of mhTERTAd.sTbRFc in a human breast xenograft model. MDA-MB-231 human xenograft tumors were established in nude mice. mhTERTAd.sTbRFc, Ad(E1 À ).sTbRFc or Ad(E1 À ).Null or buffer was injected into the tail vein. Tumor sizes were measured once a week and are shown in Figure 6a . In the control group of animals, tumors grew rapidly. However, in the group of animals that received mhTERTAd.sTbRFc, there was a significant inhibition of tumor growth over time (P-value o0.01 compared with buffer control). Intravenous injection of Ad(E1 À ).sTbRFc Oncolytic adenovirus for breast cancer therapy Z Hu et al showed some inhibition of tumor growth; however, the inhibition of tumor growth in the Ad(E1 À ).sTbRFctreated group of animals was not statistically significant compared with that in the buffer-treated group (P-values 40.05). Ad(E1 À ).Null had no significant inhibition on tumor growth (P-value 40.05) compared with the buffer group, suggesting that the antitumor responses of mhTERTAd.sTbRFc require viral replication in addition to sTGFbRIIFc production.
To examine whether the intravenous delivery of mhTERTAd.sTbRFc in the experiments described above produces high levels of sTGFbRIIFc, we collected blood samples at the end of the experiment (day 35). Aliquots of blood samples were analyzed for the presence of sTGFbRIIFc using the ELISA method described in Materials and methods. In the mhTERTAd.sTbRFctreated group, the levels of sTGFbRIIFc present in blood were 17.64 ± 3.99 mg ml À1 (Figure 6b) . Similarly, the E1 À Ad.sTbRFc-treated group also produced high levels (9.45±2.59 mg ml À1 ) of sTGFbRIIFc ( Figure 6b ). As expected, animals that received buffer or Ad(E1 À ).Null had very low levels of sTGFbRIIFc (less than 5 ng ml À1 ) in blood. These results show that the intravenous delivery of mhTERTAd.sTbRFc, as well as of sTGFbRIIFc, into mice results in the release of sTGFbRIIFc protein in blood. However, the fact that mhTERTAd.sTbRFc is more effective as an antitumor agent suggests that perhaps viral replication, as well as sTGFbRIIFc production, has an important role in inhibiting tumor growth after intravenous delivery of viral vectors.
Discussion
There is a tremendous need to create novel approaches to treat breast cancer. In recent years, tumor-specific replicating adenoviruses have been proposed as potential gene therapy vehicles to target cancer. [2] [3] [4] [5] Given that breast cancer often metastasizes to other organs, there is a need for developing replicating adenoviruses that could be administered systemically for the treatment of breast cancer. 5 Results presented here indicate that the modified hTERT promoter is relatively more specific than the CMV promoter in targeting breast cancer, strengthening the idea of using oncolytic adenoviruses in which E1A expression is controlled by the mhTERT promoter. The mhTERTAd.sTbRFc virus was created by the homologous recombination procedures previously 
.Null (.) or buffer (K). The tumor growth of various groups was compared with that of buffer control groups using two-way analysis of variance (ANOVA), and was further evaluated by Bonferroni's post hoc test using GraphPad Prism 5 software. Compared with the buffer group, the P-value for the mhTERTAd.sTbRFc group is o0.01 (*), P-value for Ad(E1 À ).sTbRFc is 40.05 and P-value for Ad(E1 Oncolytic adenovirus for breast cancer therapy Z Hu et al established in our laboratory. In vitro results suggested that cancer cells supported mhTERTAd.sTbRFc replication and viral replication was attenuated in normal cells, indicating a potential advantage to use mhTERTAd.sTbRFc for in vivo research. Another important feature of mhTERTAd.sTbRFc is that it has retained the capacity to express the sTGFbRIIFc protein. These results therefore suggest that mhTERT-driven E1A expression does not compromise the ability of mhTERTAd.sTbRFc to replicate or produce sTGFbRIIFc in breast tumor cells.
Another important finding reported here is that the adenoviral-mediated sTGFbRIIFc produced is functionally active. In vitro assays showed that sTGFbRIIFc can bind with TGFb-1, and inhibit TGFb-dependent SMAD-3 phosphorylation. The inhibition of SMAD phosphorylation production is of particular significance, as higher levels of SMAD phosphorylation are linked with the progression of breast cancer metastasis. 9, 13, 22, 23 We also report that systemic administration of mhTERTAd.sTbRFc through the tail vein causes significant inhibition of tumor growth of a human xenograft model in nude mice. mhTERTAd.sTbRFc-treated animals also produce high levels of sTGFbRIIFc in the blood, although in this limited set of animals, it is difficult to correlate mhTERTAd.sTbRFc-mediated sTGFbRIIFc expression and in vivo antitumor responses of local tumors. An important point to be noted is that a replication-defective virus when injected systemically, although also producing high levels of sTGFbRIIFc in the blood, was less effective than mhTERTAd.sTbRFc in inhibiting tumor growth. These results clearly suggest that viral replication, as well as the route of viral injection, is critical for antitumor responses, at least in this particular tumor model, as TGFb seems to have a major role in breast cancer-associated bone metastasis. [6] [7] [8] [9] [10] [11] [12] [13] Our future studies will be designed to examine the effect of mhTERTAd.sTbRFc-mediated sTGFbRIIFc protein production in causing the inhibition of bone metastasis and osteolytic bone destruction.
